InMed Pharmaceuticals

InMed Pharmaceuticals EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of InMed Pharmaceuticals (INM) as of Nov 16, 2026 is -7.71 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -7.91 M USD — a change of -2.65% (higher).

EBITDA

-7.71 MUSD

YoY

-2.65%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of InMed Pharmaceuticals is 2025 -7.71 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of InMed Pharmaceuticals was 2024 -7.91 M USD. It decreases by -2.65% higher compared to the previous year.

The InMed Pharmaceuticals EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-6.69 M USD
Jan 1, 2019
-10.22 M USD
Jan 1, 2020
-8.97 M USD
Jan 1, 2021
-9.82 M USD
Jan 1, 2022
-13.40 M USD
Jan 1, 2023
-8.18 M USD
Jan 1, 2024
-7.91 M USD
Jan 1, 2025
-7.71 M USD
The InMed Pharmaceuticals EBITDA history
YEAREBITDAYoY
-7.71 MUSD-2.65%
-7.91 MUSD-3.24%
-8.18 MUSD-38.96%
-13.40 MUSD+36.46%
-9.82 MUSD+9.48%
-8.97 MUSD-12.23%
-10.22 MUSD+52.77%
-6.69 MUSD+102.73%
-3.30 MUSD+91.86%
-1.72 MUSD-51.96%
-3.58 MUSD+211.30%
-1.15 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

InMed Pharmaceuticals Stock analysis

What does InMed Pharmaceuticals do? InMed Pharmaceuticals Inc is a biopharmaceutical company based in Vancouver, Canada, listed on the stock exchange in June 2001. The firm operates through two main segments: InMed Pharmaceuticals and BayMedica. The InMed segment focuses on the research and development of prescription-based cannabinoid products, specifically targeting diseases with high unmet medical needs. Key candidates include INM-755, a topical skin cream for Epidermolysis Bullosa, and INM-088 for glaucoma treatment. The BayMedica segment develops proprietary manufacturing technologies to produce rare cannabinoids for the health and wellness industry. The company leverages its expertise in rare cannabinoids and analogs to address significant therapeutic gaps. InMed Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about InMed Pharmaceuticals stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of InMed Pharmaceuticals is -7.71 M USD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of InMed Pharmaceuticals changed from -7.91 M USD to -7.71 M USD, representing a -2.65% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) InMed Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s InMed Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — InMed Pharmaceuticals

All Key Metrics — InMed Pharmaceuticals